semaglutide
Small Pharmacies vs Big Contracts Semaglutide Crash
The FDA’s exclusion of semaglutide, tirzepatide and liraglutide from the 503B bulk list forces small pharmacies to buy these drugs at higher prices, quickly eroding profit margins. This shift reshapes how independent retailers source GLP-1 therapies and pressures them to renegotiate contracts with specialty compilers. On April 1, 2026,